Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

An International Multicenter Open-label Clinical Study of the Safety and Efficacy of RPH-104 for Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

The purpose of this study is to assess safety and efficacy of the long-term treatment with RPH-104 at doses of 80 or 160 mg once every 2 weeks (q2w) in patients with familial Mediterranean fever (FMF) with colchicine resistance or intolerance (i.e. colchicine resistant, crFMF), who completed the core study, during which they received at least one dose of RPH-104 (i.e. study patient population).

Study Overview

• Status: Recruiting
• Conditions: Familial Mediterranean Fever; FMF
• Intervention / Treatment: Biological: RPH-104

Detailed Description

This study is a long-term open-label extension (OLE) of the core double blind randomized placebo-controlled study CL04018065. This OLE study will have the following periods:

1. Screening period - 2 weeks (from signing an Informed Consent Form [ICF] at Visit 10 of the core study to Visit 1, Day 0 of this OLE study) - includes unblinding of the treatment groups determined in the core study (unless was unblinded previously) and determination of the eligibility criteria compliance for this study (all other screening procedures are performed after the completion of Visit 11 of the core study, which is also a Day 0 of this OLE study); All patients meeting the study inclusion/exclusion criteria according to the screening results will be transferred to the treatment period at the same day (Day 0) - the beginning of this period will be considered Visit 1 of this study

2. Treatment period - All patients will be receiving RPH-104 treatment for 198 weeks in the open-label regimen (both patient and the Investigator, along with all study team will know which treatment is used) at the doses determined for them in the core study. Thus, the possible RPH-104 dose will be:

   • 80 mg q2w subcutaneously (SC);
   • 160 mg q2w SC

   The first RPH-104 administration in this study will be performed at Visit 1. To maintain the q2w dosage regimen, the screening and the first open-label injection of RPH-104 (if the patient meets the study eligibility criteria) must be performed on the same day - Day 0 (which is also the day of Visit 11 of the core study) - i.e. the first administration in this study will be performed 2 weeks (±3 days) after the last administration in the core study.

   Further, RPH-104 will be administered to patients q2w both during each scheduled visit to the study site (with safety and efficacy assessments according to the visits schedule), and during Drug Administration Visits (DAVs) at the study site or at the patient's accommodation An injection of the study drug to patients is performed by qualified medical personnel every 2 weeks when the patient visits the study site; it is also possible for the patients to self-administer the drug at home (for which patients will be appropriately trained and provided with the necessary quantity of the drug, materials for the injection (including special containers for their disposal) and proper drug transportation).

   Safety and efficacy assessments are performed at Visit 1, Visit 2 (in 2 weeks), Visit 3 (in 4 weeks), Visit 4 (in 4 weeks), Visit 5 (in 8 weeks) and thereafter every 12 weeks (Visit 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20) according to the visits schedule. In case of RPH-104 administration in patients' accommodation, telephone contacts with a patient will be conducted by the Investigator every 4 weeks in between the visits starting from the Visit 4.In case of FMF attack development, patients who receive 80 mg of the drug may be switched to the increased maximum drug dose160 mg based at the discretion of the investigator.

   The drug is administered only at scheduled visits. Dose reduction of RPH-104 is not allowed in this study. After patients receive the last dose of RPH-104 at Week 198 of the study, the treatment period will be considered completed and an 8-week safety follow-up will start

3. Safety follow-up period - 8 weeks. During this period the patients will have to visit the study site twice in 4 weeks (Visit 21) and 8 weeks (Visit 22) after the last RPH-104 dose for safety assessments.

The last visit of the safety follow-up period (Visit 22) is the End of Study Visit; after completion of all procedures of this visit, patients will be considered to have completed the study.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Yulia Karpova; Phone Number: 1197 +7 495 956 79 37; Email: jn.karpova@inbox.ru
• Study Contact Backup: Name: Marina Beloukhova; Phone Number: +7 495 956 79 37; Email: beloukhova@partners.rpharm.ru

Study Locations

• Armenia
  • Yerevan, Armenia, 0001
    • Recruiting
    • Center of Medical Genetics and Primary Health Care LLC
• Russian Federation
  • Moscow, Russian Federation, 119048
    • Recruiting
    • FSBEI HE First Moscow State Medical University named after I.M. Sechenov
  • Moscow, Russian Federation, 125284
    • Recruiting
    • Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin
  • St.Petersburg, Russian Federation, 191025
    • Recruiting
    • Medical Technologies Ltd.
  • Stavropol', Russian Federation, 355000
    • Recruiting
    • Terafarm, Llc
• Turkey
  • Ankara, Turkey, 06230
    • Recruiting
    • Hacettepe University Faculty of Medicine
  • Istanbul, Turkey, 34098
    • Recruiting
    • Istanbul University Cerrahpaşa Faculty of Medicine
  • Istanbul, Turkey, 34093
    • Recruiting
    • Istanbul University Istanbul Faculty of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. The patient with Familial Mediterranean Fever (FMF) with resistance to or intolerance of colchicine, who completed the core study, during which he/she received at least one dose of RPH-104.
2. Voluntarily signed and dated Patient Informed Consent Form (ICF) for participation in this study.

3. The patient's ability and desire, according to the Investigator's discretion, to follow the schedule of visits, follow the study procedures and follow the Protocol requirements, including the following:

   • to visit the study site every 2 weeks for RPH-104 administration by qualified study site personnel

or

• to learn the subcutaneous (SC) injection technique and self-administer RPH-104 at his/her accommodation as per the study Protocol

or

• to agree with the qualified medical personnel visits to his/her accommodation for RPH-104 administration.

Exclusion Criteria:

1. Any medically significant event that was observed in a patient during his/her participation in the core study, as well as any other medical conditions (including psychiatric disorders) or laboratory abnormalities, which may increase the potential risk associated with participation in the study and treatment with RPH-104, or may affect the interpretation of the study results, and which, according to the Investigator's opinion, may lead to the patient's non-compliance with the study inclusion criteria.
2. Pregnant and/or lactating women or women planning pregnancy during the study or within 2 months after the last RPH-104 dose.

3. Women of childbearing potential, i.e. all females with physiological ability to conceive except for those with final cessation of menses, which should be determined retrospectively after 12 months of natural amenorrhea, i.e. amenorrhea with an appropriate clinical status, for example, at respective age, who do not agree to use highly effective contraceptives throughout the study, starting from the moment of signing the ICF and for at least 8 weeks after the last RPH-104 dose or Men who are sexually active and do not agree to use highly effective contraceptives throughout the study, starting from the moment of signing the ICF and for at least 8 weeks after the last RPH-104 dose.

   Highly effective contraception methods include:

   • complete abstinence: if it corresponds to the preferred and conventional lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation method) and interrupted coitus are not considered acceptable contraceptive methods;
   • female sterilization: surgical bilateral ovariectomy (with/without hysterectomy) or tubal ligation at least 6 weeks before the start of the core study. In a case of ovariectomy only, the female reproductive status should be verified by further hormonal test;
   • male sterilization (with documented absence of sperm in ejaculate post vasectomy) at least 6 months before the start of the core study. Vasectomized male partner should be the only partner of the participating female subject;

   • combination of any two of the following methods (a+b or a+c or b+c):

     1. use of oral, injectable or implanted hormonal contraceptives; in a case of oral contraceptives, the woman should constantly use the same product as was used during the core study;
     2. installation of an intrauterine device or contraceptive system;
     3. use of barrier contraceptives: condom or occlusive cap (diaphragm or cervical cap/contraceptive vaginal ring) with spermicidal foam/gel/film/cream/vaginal suppository

4. The need for a therapy with any of the following products from the moment of signing the ICF till the study treatment period completion:

   • systemic glucocorticoids at a dose exceeding 0,2 mg/kg/day of prednisolone (or 0,16 mg/kg/day of methylprednisolone, or an equivalent dose of another glucocorticoid) orally;
   • rilonacept, tocilizumab, rituximab, canakinumab, tumor necrosis factor alpha (TNF-a) inhibitors (TNFi) and other biological products (except for RPH-104);
   • immunosuppressants (cyclosporine, methotrexate, leflunomide, thalidomide, azathioprine, 6-mercaptopurine, cyclophosphamide, etc.);
   • methylprednisolone (or an equivalent) at a dose of more than 40 mg/day parenterally;
   • intramuscular, intra-articular or peri-articular administration of glucocorticoids;
   • anakinra;
   • tofacitinib, baricitinib;
   • any experimental drugs (except for RPH-104)
5. The need to use a live (attenuated) vaccine during the study or within 3 months after the last RPH-104 dose. Live attenuated vaccines include vaccines against viruses: measles, rubella, mumps, chickenpox, rotavirus, flu (as a nasal spray), yellow fever, polio (oral polio vaccine); vaccines against tuberculosis (BCG), typhoid fever (oral typhoid vaccine) and typhus (typhus vaccine). Immunocompetent family members of the patient should not be vaccinated with the oral polio vaccine during the patient's participation in the study
6. Positive results of tuberculosis screening performed at Visit 10 of the core study (QuantiFERON-Tuberculosis(TB)/T-Spot.TB test, chest X-ray).
7. Participation in other experimental studies (except for the core study).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: RPH-104 q2w; RPH-104 80 mg once every 2 weeks subcutaneously or RPH-104 160 mg once every 2 weeks subcutaneously	Biological: RPH-104; solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term		Up to 62 weeks
Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term		Up to 62 weeks
Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI), by System Organ Class and Preferred Term		Up to 62 weeks
Incidence rate for serious adverse events (SAEs)	Incidence rate, expressed as the number of events per 100 patient-years of follow-up, for SAEs	Up to 62 weeks
Incidence rate for adverse events of special Interest (AESI)	Incidence rate, expressed as the number of events per 100 patient-years of follow-up, for AESI	Up to 62 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of patients with physician global assessment of disease activity scale (PGA) <2	PGA of disease activity involves a 5-point system: from 0 = no clinical signs and symptoms associated with the disease to 4 = severe clinical signs and symptoms associated with the disease.	Up to 62 weeks
Percentage of patients with serological remission	Serological remission is defined as C-reactive (CRP) level ≤10 mg/L.	Up to 62 weeks
Percentage of patients whose Serum amyloid A (SAA) levels returned to normal values	SAA normal levels are defined as SAA <10 mg/L	Up to 62 weeks
Percentage of patients who have experienced ≥ 1 attacks per month (since Day 0)	Criteria for the diagnosis of an attack are defined as the simultaneous development of clinical and serological signs of an attack, including: the score on the scale of global physician's assessment of disease activity (PGA) ≥ 2, suggesting "mild", "moderate" or "severe" activity of the disease (i.e., clinical signs), AND; CRP level ≥ 30 mg/L (i.e. serological signs)	Up to 54 weeks
Percentage of patients who have not had a single attack	Criteria for the diagnosis of an attack are defined as the simultaneous development of clinical and serological signs of an attack, including: the score on the scale of global physician's assessment of disease activity (PGA) ≥ 2, suggesting "mild", "moderate" or "severe" activity of the disease (i.e., clinical signs), AND; CRP level ≥ 30 mg/L (i.e. serological signs)	Up to 54 weeks
Percentage of patients escalated to RPH-104 160 mg q2w dose	The dose may be increased if a new attack is confirmed	Up to 54 weeks
Percentage of patients receiving additional symptomatic therapy with NSAIDs, paracetamol or glucocorticoids due to FMF	Symptomatic therapy was prescribed by the decision of the investigator upon confirmation of a new attack	Up to 62 weeks
Change in the inflammatory markers CRP compared to baseline	CRP level mg/l at each visit	Up to 62 weeks
Change in the inflammatory markers SAA compared to baseline	SAA level mg/l at each visit	Up to 62 weeks
Changes in the PGA score over time	PGA of disease activity involves a 5-point system: from 0 = no clinical signs and symptoms associated with the disease to 4 = severe clinical signs and symptoms associated with the disease.	Up to 54 weeks
Changes in the severity of chest pain based on the main disease symptoms scale.	An assessment of severity of the main symptoms of the disease will be based on a 5-point scale: 0 = no symptom, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe	Up to 54 weeks
Changes in the severity of abdominal pain based on the main disease symptoms scale.	An assessment of severity of the main symptoms of the disease will be based on a 5-point scale: 0 = no symptom, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe	Up to 54 weeks
Changes in the severity of arthralgia/arthritis based on the main disease symptoms scale.	An assessment of severity of the main symptoms of the disease will be based on a 5-point scale: 0 = no symptom, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe	Up to 54 weeks
Changes in the severity of skin rash based on the main disease symptoms scale.	An assessment of severity of the main symptoms of the disease will be based on a 5-point scale: 0 = no symptom, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe	Up to 54 weeks
Changes in the renal function in patients with impaired renal function at the screening	Impaired renal function is defined as creatinine clearance(ClCr) <90 ml/min [calculated using the Cockcroft-Gault formula] at the screening	Up to 62 weeks
Changes in proteinuria in patients with baseline proteinuria	Presence of protein in urine according to urinalysis results	Up to 62 weeks

Collaborators and Investigators

• Sponsor: R-Pharm International, LLC
• Collaborators: Atlant Clinical LLC; Data Management 365; Exacte Labs LLC; R-Pharm JSC; Key Stat LLC; TRPharm İlaç Sanayi Ticaret Anonim Şirketi and ASCOT SCIENCE Education and Consulting Ltd.; Unimed Laboratories
• Investigators: Study Director: Mikhail Samsonov, R-Pharm

Study record dates

Study Major Dates

• Study Start (Actual): October 5, 2021
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): January 1, 2029

Study Registration Dates

• First Submitted: November 3, 2021
• First Submitted That Met QC Criteria: January 12, 2022
• First Posted (Actual): January 13, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 10, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: subcutaneous; RPH-104; colchicine inefficacy; colchicine intolerance; colchicine resistance; FMF; interleukin-1 inhibitor
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Infections; Skin Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Negative Bacterial Infections; Skin Diseases, Genetic; Body Temperature Changes; Fever; Brucellosis; Familial Mediterranean Fever; Hereditary Autoinflammatory Diseases
• Other Study ID Numbers: CL04018071

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No